Streptococcus pneumoniae (SP) causes widespread diseases including meningitis & pneumonia. Current antibiotics are ineffective against resistant strains and, if effective, can cause excessive inflammation, increasing mortality and long-term effects (e.g. brain damage) in survivors. With a market size of >$2B, meningitis & (severe) pneumonia are linked to high mortality & treatment costs (up to 50%; >$50K per episode) demanding novel treatments complementary to antibiotics. Our approach seeks to fill this gap by offering bacterial reduction and synergies with antibiotics while also reducing inflammation. Our team comprises Assoc. Prof. L. Hathaway (Univ. Bern; SP expert) and 2 business executives with > 25 years of biotech/pharma experience (K. Alevizopoulos, G. Fotopoulos).